Chutes & Ladders—Bayer provides Roche veteran Rommel as analysis head

0
29

               
Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings all through the trade. Please ship the great phrase—or the unhealthy—out of your store to Kyle Blankenship, and we are going to characteristic it right here on the finish of every week.


Roche’s main most cancers analysis exec Rommel jumps ship to Bayer as Moeller exits

Bayer
Christian Rommel, Ph.D., comes on board as head of analysis.

Rommel involves Bayer from Roche, the place he served because the Swiss main’s senior vp and head of oncology analysis and early growth for practically seven years. He’s additionally served stints at Amgen, Intellikine, Merck Serono and Regeneron. Now, he lands at Bayer recent off a brand new concentrate on gene therapies and poised from Feb. 1 subsequent yr to take over from former R&D chief Joerg Moeller, M.D., who will formally exit at year-end. Moeller has “determined to depart Bayer … to pursue different profession alternatives,” in keeping with the corporate, so don’t be shocked if he turns up at one other biopharma quickly. Fierce Biotech

Webinar

Digitize distant website monitoring with Field

Field will talk about how your life sciences group can proceed to propel therapies & gadgets by the worth chain with quicker and much more safe website monitoring and auditing.


Cogent Biosciences names Array veteran Robbins to CEO put up

Cogent Biosciences
Andrew Robbins has been named CEO. 

Robbins served at Array Biopharma as chief working officer, the place he was accountable for the commercialization of two novel precision oncology merchandise earlier than Array’s acquisition by Pfizer in 2019. Previous to becoming a member of Array, Robbins held administration positions at each Hospira, a world pharmaceutical and medical gadget firm, and Pfizer, as a part of its oncology enterprise unit. He presently serves on the board of administrators for Harpoon Therapeutics and Turmeric Acquisition Company. Launch


Nuvation Bio brings on Fox as latest chief monetary officer 

Nuvation Bio
Jennifer Fox
will take over the CFO position. 

Fox shall be a member of the chief management group and shall be accountable for company technique, enterprise growth, investor relations and company communications. She joins Nuvation from CitiGroup, the place she most just lately served as a managing director and co-head of the healthcare company and funding banking group. Previous to CitiGroup, Fox held senior positions in funding banking at Deutsche Financial institution, Bear Stearns, Financial institution of America and Prudential Securities. Launch


> London-based Adaptate Biotherapeutics has named Stewart Kay as chief enterprise officer. Kay was most just lately CBO at Crescendo Biologics and previous to that served as senior director of transactions at GlaxoSmithKline. 

> French biotech SparingVision has appointed Florence Lorget, Ph.D., as chief growth sciences officer and Rajiv Gangurde, Ph.D., as chief know-how officer. Launch

> Farmingdale, New York-based Codagenix will deliver on Jeffrey Fu, Ph.D., as chief enterprise officer. Fu spent practically 30 years at Merck & Co., the place he led the corporate’s North America pharmaceutical and international vaccine business enterprise growth actions. Launch

> Boston-based GentiBio has tapped Catherine Thut as chief enterprise officer and Thomas Wickham as chief scientific officer. Launch

> Boston-based Monte Rosa Therapeutics has fleshed out it government group with the appointments of Min Wang, Ph.D., as chief working officer; Ajim Tamboli as chief monetary officer; and Jullian G. Jones, Ph.D., as senior VP and head of enterprise growth. Launch

LEAVE A REPLY

Please enter your comment!
Please enter your name here